Skip to main content

Table 3 Estimates of hazard ratio with multivariate analysis in HER2+/ER– and core basal subtypes, stratified by CD8+ iTIL status

From: Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration

Variable

Whole subgroup

With CD8+ iTIL = 0

With CD8+ iTIL ≥ 1

 

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HER2+/ER–

 

Age

1.13

0.573

1.09

0.741

1.12

0.784

≥50 vs. <50

(0.74 - 1.73)

 

(0.65 - 1.84)

 

(0.50 - 2.50)

 

Grade

2.23

0.007

2.05

0.039

2.55

0.134

3 vs. (1 and 2)

(1.24 - 4.01)

 

(1.04 - 4.07)

 

(0.75 - 8.65)

 

Tumor size

1.67

0.026

1.43

0.198

2.53

0.025

>2 cm vs. ≤2 cm

(1.06 - 2.61)

 

(1.83 - 2.48)

 

(1.13 - 5.67)

 

Nodal status

1.95

0.008

1.20

0.588

3.87

0.002

Positive vs. negative

(1.19 - 3.21)

 

(0.62 - 2.35)

 

(1.67 - 8.96)

 

LVI

1.34

0.250

1.47

0.261

1.56

0.268

Positive vs. negative

(0.82 - 2.19)

 

(0.75 - 2.85)

 

(0.71 - 3.40)

 

FOXP3+ iTIL

0.71

0.104

0.84

0.528

0.48

0.047

≥2 vs. <2

(0.46 - 1.07)

 

(0.48 - 1.49)

 

(0.23 - 0.98)

 

Core basal

 

Age

1.01

0.957

0.77

0.301

1.53

0.245

≥50 vs. <50

(0.68 - 1.50)

 

(0.47 - 1.26)

 

(0.75 - 3.12)

 

Grade

1.30

0.417

1.55

0.257

1.91

0.387

3 vs. (1 and 2)

(0.69 - 2.44)

 

(0.73 - 3.28)

 

(0.44 - 8.22)

 

Tumor size

1.62

0.020

2.81

<0.001

0.77

0.470

>2 cm vs. ≤2 cm

(1.08 - 2.43)

 

(1.67 - 4.72)

 

(0.38 - 1.57)

 

Nodal status

2.37

<0.001

2.95

<0.001

1.64

0.212

Positive vs. negative

(1.53 - 3.66)

 

(1.68 - 5.17)

 

(0.75 - 3.56)

 

LVI

1.37

0.159

0.86

0.604

3.60

0.003

Positive vs. negative

(0.88 - 2.13)

 

(0.49 - 1.51)

 

(1.56 - 8.29)

 

FOXP3+ iTIL

0.53

0.002

0.66

0.130

0.93

0.845

≥2 vs. <2

(0.36 - 0.79)

 

(0.39 - 1.13)

 

(0.43 - 2.00)

 
  1. CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; HER2, human epidermal growth factor receptor-2; iTIL, intratumoral tumor-infiltrating lymphocyte; LVI, lymphovascular invasion.